Infection Prevention and Control Policy on the Management of Patients with Tuberculosis

To provide clinical staff with guidelines for management of TB infected cases and to identify strategies for the prevention and control of cross infection to other patients, staff and visitors.

V4.0

July 2016
Management of an in-patient with suspected or confirmed Pulmonary Tuberculosis

Admit to Wheal Prosper Ward (if agreed with Respiratory Consultants) or Polkerris. When this is not possible, the patient must be nursed in a single room.

Submit specimens as requested by Clinicians.

When multi Drug Resistant TB (MDR TB) is suspected/confirmed the patient must be nursed on Wheal Prosper Ward until transfer to a specialist centre with negative isolation facilities.

The patient must be given respiratory hygiene advice and ensure the patient has tissues, waste disposal and hand hygiene facilities available.

Request the patient wears a surgical mask when they leave the isolation room.

Ensure the patient is aware isolation will continue until at least 2 weeks of treatment has been completed and there has been a clinical improvement

Or

The patient has 3 consecutive sputum smear negative samples and is asymptomatic

PPE for staff:

Non sterile gloves and apron.

Masks are not required for casual short contact.

Surgical masks to be worn for prolonged close contact.

FFP3 mask to be worn during aerosol generating procedures i.e. bronchoscopy, sputum induction or nebuliser treatment.

FFP3 masks must be worn when entering a room if MDR TB is suspected/confirmed.
# Table of Contents

1. **Introduction** ........................................................................................................................................... 4
2. **Purpose of this Policy** ............................................................................................................................. 4
3. **Scope** ..................................................................................................................................................... 4
4. **Definitions** ............................................................................................................................................ 4
5. **Ownership and Responsibilities** .......................................................................................................... 5
   5.1. **Roles of the Managers** .......................................................................................................................... 5
   5.2. **Health care personnel** .......................................................................................................................... 5
   5.3. **The Infection Prevention and Control Team** ....................................................................................... 5
   5.4. **The Occupational Health Department** .............................................................................................. 5
   5.5. **Consultant Medical Staff** .................................................................................................................. 5
   5.6. **Role of the Hospital Infection Prevention & Control Committee** ..................................................... 5
6. **Standards and Practice** ........................................................................................................................... 5
   6.1. **How is TB Infection Spread?** .............................................................................................................. 5
   6.2. **Latent TB** ........................................................................................................................................... 6
   6.3. **Infectious Pulmonary TB** .................................................................................................................... 6
   6.4. **Identification of Patients** .................................................................................................................... 6
   6.5. **Non Infectious TB** .............................................................................................................................. 7
   6.6. **Multi-Drug Resistant TB (MDR TB)** ................................................................................................. 7
   6.7. **Risk Factors for Developing MDR TB** ............................................................................................... 7
   6.8. **Extensively Resistant TB** .................................................................................................................. 8
   6.9. **Extra-Pulmonary TB** .......................................................................................................................... 8
   6.10. **Pulmonary TB Investigations** ........................................................................................................... 8
   6.11. **Patient Isolation** .............................................................................................................................. 9
   6.12. **In- Patient Isolation Flowchart** ....................................................................................................... 10
   6.13. **Practice Recommendations** ........................................................................................................... 10
   6.14. **Contact Tracing and Respiratory TB Risk Assessment** ................................................................... 13
   6.15. **Treatment for Infectious TB Patient Cases** .................................................................................... 14
   6.16. **Management of non-compliant Patients** ........................................................................................ 14
   6.17. **Transfer/Discharge Home** ............................................................................................................... 15
7. **Dissemination and Implementation** ......................................................................................................... 15
8. **Monitoring compliance and effectiveness** .............................................................................................. 15
9. **Updating and Review** ............................................................................................................................. 16
10. **Equality and Diversity** .......................................................................................................................... 16

**Appendix 1. Governance Information** .................................................................................................... 17
**Appendix 2. Initial Equality Impact Assessment Screening Form** ................................................................. 20
1. Introduction

1.1. Tuberculosis (TB) is an infectious disease caused by the organism Mycobacterium Tuberculosis, incidence in the UK remains high compared with other Western European countries (NICE 2016). It usually presents as a respiratory disease affecting lungs, larynx, pleura or mediastinal lymph nodes. It can also affect bones and joints, the gastrointestinal and renal tracts, the central nervous system or be disseminated through the blood stream. TB can present a health risk to staff if they become infected from patients; staff can also infect patients.

People at an increased risk of developing active TB include:
- People with HIV, diabetes, chronic kidney disease, or silicosis or receiving haemodialysis.
- Children younger than 5 years old
- People with excessive alcohol intake or who are injecting drug users
- People who have had solid organ transplantation
- People who have a haematological malignancy or are receiving chemotherapy
- People who have had a gastrectomy or jejunileal bypass
- People who are having treatment with anti-tumour necrosis factor alpha or other biologic agents

1.2. Resistance to TB drug treatment can develop, and in some cases multi-drug resistance (MDR TB) develops if patients are not compliant with medication. All patients with TB should have risk assessments for drug resistance and all patients should be tested for HIV (NICE 2011).

1.3. Tuberculosis is a notifiable disease. The medical staff attending the patient have a legal responsibility to notify a case of TB as soon as the diagnosis is made and a decision to commence full treatment is taken.

2. Purpose of this Policy

The purpose of the document is to provide clinical staff with guidelines for management of TB infected patients and to identify strategies for the prevention and of infection to other patients, staff and visitors.

3. Scope

The policy applies to all staff working within the hospitals of the Royal Cornwall Hospital NHS Trust.

4. Definitions

Definitions are contained within the text.
5. Ownership and Responsibilities

5.1. **Roles of the Managers**
Associate Directors/clinical leads must ensure that resources are available for healthcare workers to undertake effective standard and isolation precautions pertinent to TB.

5.2. **Health care personnel**
Have a clinical and ethical responsibility to carry out effective infection prevention and control procedures applicable to the control of TB and to act in a way which minimises risk to the patient.

5.3. **The Infection Prevention and Control Team**
Is responsible for providing expert advice in accordance with this policy, for supporting staff in its implementation, and assisting with risk assessment where complex decisions are required. The team is responsible for ensuring this policy remains consistent with the evidence-base for safe practice, and for reviewing the policy on a regular basis.

The Infection Prevention and Control team are responsible for contact tracing in the event of a case being identified in the hospital.

5.4. **The Occupational Health Department**
Is responsible for ensuring that all new healthcare workers have standard health clearance before they have clinical contact with patients i.e. be free from TB disease.

Is responsible for the follow up of any member of staff who have been identified as a contact.

5.5. **Consultant Medical Staff**
Are responsible for ensuring their junior staff read and understand this policy, and adhere to the principles contained in it at all times.

5.6. **Role of the Hospital Infection Prevention & Control Committee**
The Hospital Infection Prevention and Control Committee are responsible for approving this document. The Hospital Infection Prevention & Control Committee is responsible for the monitoring of this policy.

6. Standards and Practice

6.1. **How is TB Infection Spread?**
People who have active infectious (open) pulmonary TB expel small respiratory droplets when coughing and sneezing. These small droplet nuclei, carried by air currents can be inhaled by exposed people and cause infection. Young children with TB are thought to be less infectious than older subjects.
6.2. **Latent TB**

The presence of dormant live bacilli, which can live in the lungs or other parts of the body without causing active disease, is referred to as latent TB. Latent TB cases are not infectious to others. People who have been exposed to TB and who have strongly positive Mantoux skin tests (disproportionate to their BCG status) and/or positive interferon gamma blood tests and who have no clinical signs or symptoms of disease, and a normal Chest X-ray, may be regarded as having latent TB.

6.3. **Infectious Pulmonary TB**

6.3.1. Primary TB occurs following exposure to another individual with active pulmonary TB. Clinical diseased occurs within a few months of exposure.

6.3.2. Latent TB may reactivate and cause active TB disease this is called post – primary TB. It can occur many years after initial exposure and is more likely to occur if the patient becomes immune suppressed (e.g. Anti Tumor Necrosis Factor, TNF, therapy). If reactivation occurs in the lungs it may be infectious.

6.3.3. Pulmonary TB may be sputum smear positive or negative for Acid and Alcohol Fast Bacilli (AAFB). The highest risk of transmission occurs when patients are smear positive.

6.3.4. TB is generally a sub-acute illness with patients being unwell for several weeks or months prior to diagnosis.

Common symptoms include;
- Fevers
- Night Sweats
- Weight loss
- Malaise
- Cough
- Haemoptysis

CXR may show upper lobe infiltrates, cavitating lesions or pleural effusion.

6.4. **Identification of Patients**

Clinicians need to ask three questions:

1. **Does the patient have tuberculosis?**

   **Suspected:** Clinical signs and symptoms or radiological changes suggestive of tuberculosis.

   **Confirmed:** Clinical signs and symptoms suggestive of TB, AAFB smear positive and/or culture positive.
2. If so, is the patient likely to be infectious?

**High risk of transmission**: Sputum smear positive.

**Low risk of transmission**: Sputum smear negative, culture positive or cultures awaited.

**Minimal risk of transmission**: Extra-pulmonary disease.

3. Is the patient likely to have drug resistant disease?

**Suspected:**
- Previous treatment.
- Contact with known resistant case.
- Acquisition in areas with high resistance rates (Africa, Former USSR and Eastern Europe, India, China)
- HIV positive patient.
- Failure of clinical response.
- Prolonged culture positive while on treatment.

**Confirmed:** Laboratory confirmation of drug resistance.

Where a child is admitted to hospital with suspected active TB any visitors to the child should be assessed for symptoms of infectious TB and kept separate from other people until they have been excluded as a source of infection.

6.5. *Non Infectious TB*

Patients are usually considered non-infectious within 2 weeks if compliant with treatment and if fevers settle, even though Bacilli may still be found in sputum (excluding MDR TB cases).

6.6. *Multi-Drug Resistant TB (MDR TB)*

MDR TB is defined as resistance to both rifampicin and isoniazid with or without additional drug resistances. Primary resistance can occur in people who have contracted TB from someone who is already infected with a drug resistant strain, without ever having a prior treatment history.

Resistance can also develop due to inadequate drug treatment being prescribed and as a result of non compliance with treatment.

Treatment failure is defined when cultures are positive after 4 months of treatment. These cases have a high chance of developing drug resistance. Resistance can develop to a single drug e.g. to Isoniazid.

6.7. *Risk Factors for Developing MDR TB*

- HIV positive people.
- Previous TB treatment especially if prolonged, incomplete or non compliant. Treatment failure (patient remains smear positive and symptomatic after 4 months of compliant treatment)
- Contact with a known case of drug-resistant TB
- Birth in a foreign country where there is a high incidence of TB
- Residence in London
- Age profile, with highest rates between 25-44 years and male gender
- Homeless people or living in hostels
- Substance misuse
- Contact with prison

Although drug resistance can prolong the period of infectiousness to others as well as compromising the effectiveness of treatment, MDR TB is not more infectious than drug sensitive TB (Pratt et al 2007). MDR TB is rare in the UK making up less than 1% of cases.

6.8. **Extensively Resistant TB**
Extensively drug-resistant (XDR) TB is defined as resistance to at least; rifampicin, isoniazid, quinolones and aminoglycosides. Successful treatment depends on the sensitivities for the remaining second and third line agents. XDR TB is very rare in the UK.

6.9. **Extra-Pulmonary TB**
TB can affect nearly every organ. Common forms of extra-pulmonary TB are Lymph node TB, Gastro-intestinal TB, Spinal TB and Joint TB.

All patients with extra-pulmonary TB should be referred for site specific investigation and have a chest X-ray and if possible a sputum specimen to exclude or confirm the presence of concomitant pulmonary TB.

Most non-respiratory forms of TB have a lower risk of transmission than respiratory disease. Transmission can however occur following direct contact with infected body fluid e.g. open leg ulcer or from wound ooze from an excised neck gland. Isolation is not usually required unless aerosols are generated during wound irrigation.

6.10. **Pulmonary TB Investigations**
If TB is suspected patients should also have the following investigations performed;
- Posterior-anterior chest X-ray. A thorax CT scan should be considered if Pulmonary TB is suspected.
- At least 3 sputum samples (one early morning for 3 days) for AAFB microscopy and mycobacterial culture.
- Adults who are unable to provide sputum sample should have bronchoscopy with BAL sent for AAFB smear and culture.
- For children who are unable to provide sputum sample 3 gastric lavages or 3 samples of induced sputum for AAFB microscopy and mycobacterial culture, preferably one morning sample.
- Rapid diagnostic nucleic acid amplification tests (NAAT) should be requested in certain circumstances – please refer the NICE guidelines 2016
- Treatment may be started while waiting for test results on clinical grounds and prior to obtaining a specimen provided that a specimen is sent within one week of starting treatment.

Rapid diagnostic tests can be carried out if there is a risk of MDR TB. The laboratory can perform sputum smear tests every day. Sputum/tissue culture is continued for 12 weeks.
Weight loss and a persistent cough (over 4 weeks) may be the only signs of active disease. Any patient with these symptoms that is not responding to antibiotics should be investigated for TB. Advice should be sought from Microbiology, Infectious disease or Respiratory Physicians.

6.11. **Patient Isolation**

6.11.1. The number of visit and duration of visits a person with TB makes to an outpatient department while they are still infectious should be minimised. The person should be seen at times or places away from other people.

6.11.2. On identification of any hospitalised patients with suspected or confirmed TB a decision will be made about appropriate placement, based on a risk assessment, by the Infection Prevention and Control Team and the Respiratory Consultant.

Patients with suspected or confirmed Pulmonary Tuberculosis (caused by M.TB complex), or extra-pulmonary TB when MDR TB is suspected or pulmonary involvement hasn’t been excluded, need to be assessed for transmission risk by a Respiratory Consultant/Paediatrician and IPAC Team to determine appropriate placement.

Waiting time for isolation must be kept to a minimum. This may involve prioritising their care above other patients.

It is recommended people with suspected infectious or confirmed pulmonary TB should not be admitted to a ward containing people who are immuno-compromised.

High risk patients, and patients admitted non-electively with suspected pulmonary TB who have not yet been assessed by a respiratory physician, should be managed on Wheal Prosper Ward/in a cubicle on Polkerris Ward. The Respiratory Team/Paediatric Respiratory Team must be informed within 24 hours of admission.

Whilst the highest risk of transmission occurs with smear positive patients, smear negative patients with pulmonary TB may present a risk to certain patient groups.

6.11.3. The number of visit and duration of visits a person with TB makes to an outpatient department while they are still infectious should be minimised. The person should be seen at times or places away from other people.

6.11.4. Except for MDR TB, patients should be considered infectious until two weeks of appropriate anti-tuberculosis drug therapy have been completed, and be showing clinical improvement e.g. free from fever for a week and/or cough resolving.

6.11.5. If the patient has 3 consecutive sputum (induced sputum or gastric lavage) smear negative samples and is asymptomatic as outlined above he/she will not need to be isolated.
6.11.6. A patient who has suspected or confirmed MDR TB must be isolated immediately in a single room (on the isolation ward) with the door closed, until transfer to a specialist centre with facilities for isolation in a negative pressure room can be arranged. This should be arranged without delay.

6.12. **In-Patient Isolation Flowchart**

6.13. **Practice Recommendations**

6.13.1. **Isolation**
- The patient should be isolated, based on the risk assessment.
- Teach patients to cover the mouth and turn away from others when coughing.
- Provide a clinical waste bag for patient to dispose of tissues safely.
- Place an isolation card on the door of the room, maintaining confidentiality.
- Restrict visitors who have not been previously in close contact except family members who have already had exposure.
- Do not allow other patients to visit.
- Ensure effective communications between clinical teams, infection control and domestic staff.
- Pregnant staff should avoid contact with confirmed/suspected TB cases.
• If the person is not admitted to hospital they should be advised to avoid congregate settings for the first two weeks of their treatment.

6.13.2. **Sputum Specimen collection**
• Collect sputum specimens, introduced sputum or gastric lavage for AAFB in a universal container. A 5ml sample of sputum (not saliva) should be obtained, avoiding external contamination of the container. Secure the lid safely.
• Ensure that the correct details are entered on the request form.
• Staff should not be present in the room while the patient is producing a sputum specimen.
• Ensure that the specimen is placed in the appropriate plastic bag, with the request form in the separate compartment. Specimens should be transported in a rigid container to the laboratory promptly. Leaking specimens will be rejected.
• Do not send AAFB sputum samples by post.
• Deal with spills in line with the Trust Disinfectant Policy

6.13.3. **Mask, eye and face protection**
• Masks are not routinely recommended for casual short contact with TB cases (NICE 2006). Masks should only be worn based on the infection risks to staff or other patients.
• Wear a Surgical mask only for prolonged close contact e.g. 1:1 sessions with the infectious patient if the patient is unable to control coughs and is not compliant with covering his/her mouth.
• Staff should wear EN 149 FFP3 respirator when they are with a patient during aerosol generating procedures ie bronchoscopy, sputum induction or nebuliser treatment.
• Staff and visitors should wear EN 149 FFP3 respirator if there is a risk that the patient has MDR TB and for confirmed cases while the person is thought to be infectious.
• Ensure that masks are well fitted. Remove masks carefully avoiding contamination of the hands and wash the hands using soap and water.
• Do not re-use masks. Dispose of them as clinical waste, inside the isolation area.
• In-patients with suspected infectious or confirmed pulmonary or laryngeal TB must wear a mask when leaving the isolation room They must remain in isolation until they have completed two weeks of treatment and are unlikely to be rifampicin resistant or have a negative rifampicin resistance on NAAT or culture.

6.13.4. **Hand Hygiene**
• Perform hand hygiene using alcohol gel on entry and exit from the isolation area and following patient contact.
• Provide hand hygiene advice to the patient and family.
• If hands come into contact with sputum or other body fluids and contaminated items wash the hands. (See Standard Precautions Policy for further details).
6.13.5. **Gloves (non-sterile)**
- Wear gloves only when touching blood or body fluids or sputum contaminated items and specimens.
- Care should be taken when cleaning up sputum or exudates from wounds.
- Put on clean gloves just before touching mucous membranes or non-intact skin.
- Change gloves between procedures on the same patient after contact with material that may contain high numbers of Bacilli.
- Remove gloves (single use item) promptly after use and wash hands. Gloves should be disposed of as clinical waste. (see Standard Precautions Policy)

6.13.6. **Apron/ gown**
- Only wear a disposable plastic apron for procedures where there is a risk of contamination of clothing from splashing or aerosolisation.
- Remove the apron on completion of tasks and dispose of after use as clinical waste.

6.13.7. **Patient transport**
- Patients should not be transferred to other units or hospitals unnecessarily. If transfer is necessary e.g. for chest X-ray the receiving department must be informed of the infectious state of the patient in advance, to prevent exposure to susceptible patients in waiting areas.
- Inform ambulance staff prior to patient transfer.
- Infectious patients should not share vehicles with other patients.

6.13.8. **Care of Patient equipment**
- The patient should have dedicated equipment for their use, this includes spirometers and nebulisers.
- Wear gloves and aprons to handle equipment soiled with sputum or other body fluids–decontaminate the equipment as per guidance in the disinfectant policy.
- If the equipment is single use then dispose of it as clinical waste.
- Re-usable equipment must be decontaminated prior to re-use on other patients.

6.13.9. **Environment**
- Daily enhanced cleaning of the isolation area should be performed by the domestic staff using dedicated colour coded equipment.
- A terminal clean of the room and equipment will be required at the end of the isolation period and prior to occupation by another patient using a 1000 ppm available chlorine solution.

6.13.10. **Linen**
- Gloves and aprons must be worn when handling used linen, which must be disposed of as infected linen in an alginate (dissolvable) bag inside the room. The bag should be placed in a white plastic bag outside the room and sent to the laundry.
- Personal clothing must not be hand sluiced by health care workers.
- Provide infection control advice to family members taking home soiled clothing for washing.
6.14. **Contact Tracing and Respiratory TB Risk Assessment**

6.14.1. **Patient Contacts**

If a patient on an open ward is diagnosed as having smear positive TB, a risk assessment will need to be carried out to establish the infection risks to other patients, staff, family and carers. The ward manager is responsible for ensuring that the Infection Prevention and Control Team (IPAC) are notified of all hospital in-patient cases. The IPAC team will, in turn, discuss the case with the TB Specialist Nurse and the Consultant in Communicable Disease Control (CCDC).

The Infection Prevention and Control Nurse (IPCN) will visit the ward area and collect the infected patient’s case personal details, details of admission, and a list of all patient hospital contacts. Assessments and actions will depend on the following:

- Proximity of the contacts.
- Length of time exposed e.g. cumulative of 8 hours or more before isolation.
- If other patients exposed to infection are known to be unusually susceptible to infection e.g. HIV positive or immunocompromised due to other pathology.
- Known IV drug users in contact with the index case who do not know their HIV immune status may also need to be considered to be immunocompromised.
- Patients in wards may need to be treated as close contacts, similar to household or family if they share, lounge, dining and activity rooms for prolonged periods and if the index case was coughing.
- If the index case is suspected or confirmed as having MDR TB then more stringent contact tracing will need to be carried out.
- Details of patients who have been discharged from hospital will need to be included if the index case has been an in-patient for some time.

An incident meeting to discuss the case should be convened with representatives from Public Health England, TB Key Workers, IPAC team RCHT, Microbiologists, Occupational Health, Respiratory Physician and any other relevant persons or agency.

Patients who have been in contact with an infectious TB case will need to be informed and an entry made in their notes by the doctor and the patients’ GP informed.

Family contacts will be contacted by the TB Key Worker who will arrange for screening.

6.14.2. **Staff Contacts**

It is the responsibility of the ward/departmental manager to maintain an accurate record of staff (including locum and agency staff) who have had significant exposure to any suspected or confirmed case of pulmonary TB. This list will be required in the event of contact tracing and should be forwarded to the Occupational Health Department on the advice of the Infection Prevention and Control Team.

The significance and degree of infectious risks to staff should be discussed at the incident meeting which should be attended by an Occupational Health Representative.
If a member of staff reports suspicious symptoms, the individual must be referred to the Occupational Health Department as soon as possible. The Occupational health Practitioner, after taking a full clinical history, will take appropriate action including any necessary investigations.

The decision on the staff member’s fitness for work, or advice on restricted duties, will be a clinical one based on the clinical findings and the areas where he/she works. Should the clinical findings and/or investigation indicate or confirm TB infection then referral to the Lead Clinician for TB will be arranged for follow up and management.

A decision on when the individual is fit to return to work with patients will be made in conjunction with the Lead Clinician for TB.

The member of staff’s General Practitioner will be kept informed of the outcome.

If a member of staff is confirm to have contracted TB and incident meeting should be convened to determine further actions required.

6.15. **Treatment for Infectious TB Patient Cases**

Tuberculosis control is based on early identification of infection and by ensuring that patients comply with treatment. Treatment should be in discussion with the TB/Respiratory Physician and Consultant Microbiologist.

Non adherence should be reported immediately to the clinician in charge of the patient, as drug omissions can quickly lead to the development of resistance with potential high risks of transmission of MDR TB to staff, other patients and visitors. Patients should be aware that non adherence may result in an extension of treatment course. For those patients considered to be at risk of non adherence with treatment on discharge from hospital, the use of directly observed therapy (DOTS) should be discussed with the clinician and TB key worker at the earliest opportunity.

6.16. **Management of non-compliant Patients**

Patients who are non-compliant with treatment for infectious TB are likely to fall into one of the following 3 categories:

- Patients who have capacity to consent to treatment (as defined by the Mental health Capacity Act section 3) but who refuse to comply with treatment for whatever reason may need to have compulsory admission and detention to hospital to ensure that they are closely monitored under sections 37 and 38 of the Public Health Act. Compulsory medical examination can also be required under section 35 of that Act. Compulsory treatment is not allowed under the Public Health Act.

- Patients who do not have capacity to consent to treatment as defined by the Mental Capacity Act, Section 3, can usually be treated, if necessary by admission to hospital under the common law doctrine of necessity e.g. that they lack capacity to consent and that it is in their best interests that treatment should be given. Any such treatment must be in conformity with the principles of the Mental Health Capacity Act and take account of the
safeguards provided by that Act, such as the need to refer to an independent Mental Capacity Advocate in certain circumstances, or to consult with a Lasting Power of Attorney with health and welfare powers if one has been appointed.

- Patients who refuse treatment for infectious TB due to mental disorder may in some cases be detained under the Mental Health Act 1983 though any such detention must be because the patient meets the criteria for detention under that Act and is being detained either for assessment under Section 3. The Mental Health Act does not provide a power for compulsory treatment of a physical condition. If the patient is incapable of consent to treatment for TB due to their mental disorder treatment can be provided according to above.

- Patients who are thought not to be adhering to treatment may need to have compulsory admission to hospital after discussion with social services with a view to enforcing child protection measures.

6.17. **Transfer/Discharge Home**

If patients need to be transferred to other healthcare facilities the TB Key worker/Infection Control Nurse must be informed in advance. The receiving unit must be informed of the infectious state of the patient to ensure that suitable isolation facilities are available.

Patients who are due to be discharged home should have their discharge planned with the TB Key worker and Consultant Respiratory Physician/Consultant Respiratory Paediatrician to ensure that appropriate arrangements for monitoring are in place. An assessment of the risk of infection to others will need to be made e.g. if a family member is HIV positive. In this case the patient should not be discharged until:

- He/she has had 2 weeks of treatment.
- Showing clinical improvement e.g. free from fever for a week and/or cough resolved completely.
- Sputum is AAFB smear negative from 3 consecutive specimens over a 14-day period.

7. **Dissemination and Implementation**

7.1. This policy will be implemented via the following routes:

- The policy will be included in the Trust’s Document Library
- Details of this policy will be circulated to all RCHT employees via the Trust Daily bulletin.
- Details of this policy will be circulated to all Infection Prevention and Control Link Practitioners

8. **Monitoring compliance and effectiveness**

<table>
<thead>
<tr>
<th>Element to be monitored</th>
<th>Management of patients with TB in hospital and hospital contacts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead</td>
<td>IPAC Infection Prevention &amp; Control Department</td>
</tr>
<tr>
<td>Tool</td>
<td>Incident meeting</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Frequency</td>
<td>This will be convened as each case occurs</td>
</tr>
<tr>
<td>Reporting arrangements</td>
<td>Information to be provided to the incident</td>
</tr>
<tr>
<td>Acting on recommendations and Lead(s)</td>
<td>The incident meeting group will make recommendations as required</td>
</tr>
<tr>
<td>Change in practice and lessons to be shared</td>
<td>Required changes to practice will be identified and actioned. A lead member of the group will be identified to take each change forward where appropriate. Lessons will be shared with all the relevant stakeholders</td>
</tr>
</tbody>
</table>

9. **Updating and Review**
   This document will be reviewed by the Infection Prevention and Control Team every three years or earlier should a change in circumstance dictate.

10. **Equality and Diversity**
   10.1. "This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement".
   10.2. The Initial Equality Impact Assessment Screening Form is at Appendix 2.
### Appendix 1. Governance Information

<table>
<thead>
<tr>
<th><strong>Document Title</strong></th>
<th>Infection Prevention and Control Guidance on the Management of Patients with Tuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date Issued/Approved:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Date Valid From:</strong></td>
<td>1st July 2016</td>
</tr>
<tr>
<td><strong>Date Valid To:</strong></td>
<td>30th June 2019</td>
</tr>
<tr>
<td><strong>Directorate / Department responsible (author/owner):</strong></td>
<td>Infection Prevention &amp; Control Team</td>
</tr>
<tr>
<td><strong>Contact details:</strong></td>
<td>01872 25 4969</td>
</tr>
<tr>
<td><strong>Brief summary of contents</strong></td>
<td>To reduce the risk of transmission of mycobacterium tuberculosis to patients, staff and others. To provide clinical staff with guidelines for management of TB infected cases and to identify strategies for the prevention and control of cross infection to other patients, staff and visitors. To reduce mycobacterium tuberculosis transmission and infection.</td>
</tr>
<tr>
<td><strong>Suggested Keywords:</strong></td>
<td>mycobacterium tuberculosis TB</td>
</tr>
<tr>
<td><strong>Target Audience</strong></td>
<td>RCHT</td>
</tr>
<tr>
<td><strong>Executive Director responsible for Policy:</strong></td>
<td>Executive Director of Nursing</td>
</tr>
<tr>
<td><strong>Date revised:</strong></td>
<td>01.07.2016</td>
</tr>
<tr>
<td><strong>This document replaces (exact title of previous version):</strong></td>
<td>Infection Prevention and Control Guidance on the Management of Patients with Tuberculosis Version 1</td>
</tr>
<tr>
<td><strong>Approval route (names of committees)/consultation:</strong></td>
<td>Infection Prevention and Control Steering Group Hospital Infection Prevention and Control Committee</td>
</tr>
<tr>
<td><strong>Divisional Manager confirming approval processes</strong></td>
<td>Christine Perry</td>
</tr>
<tr>
<td><strong>Name and Post Title of additional signatories</strong></td>
<td>‘Not Required’</td>
</tr>
<tr>
<td><strong>Signature of Executive Director giving approval</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Publication Location (refer to Policy on Policies – Approvals and</strong></td>
<td>Internet &amp; Intranet</td>
</tr>
<tr>
<td>Ratification:</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Document Library Folder/Sub Folder</td>
<td>Clinical / Infection Prevention &amp; Control</td>
</tr>
<tr>
<td>Links to key external standards</td>
<td>CQC Outcome 8</td>
</tr>
</tbody>
</table>

### Related Documents:


- Royal College of Nursing (2012) *Tuberculosis Case management & Cohort*
Version Control Table

<table>
<thead>
<tr>
<th>Date</th>
<th>Version No</th>
<th>Summary of Changes</th>
<th>Changes Made by (Name and Job Title)</th>
</tr>
</thead>
<tbody>
<tr>
<td>23.10.12</td>
<td>2</td>
<td>Reformatted. Reviewed and minor amendments made – section 1, section 5 and section 6.</td>
<td>Louise Dickinson Consultant Nurse Infection Prevention and Control</td>
</tr>
<tr>
<td>01.07.14</td>
<td>3</td>
<td>Updated and reformatted</td>
<td>Louise Dickinson Consultant Nurse Infection Prevention and Control</td>
</tr>
<tr>
<td>26.04.16</td>
<td>4</td>
<td>Reviewed and updated. Minor amendments to 1.1,5,6.1,6.14,7.1</td>
<td>Jean James, Clinical Nurse Specialist, Infection Prevention and Control</td>
</tr>
<tr>
<td>01.07.16</td>
<td>5</td>
<td>Reviewed and updated. Minor amendments to 6.1, 6.10, 6.11.2, 6.11.5, 6.12, 6.13.2, 6.13.86.16, 6.17</td>
<td>Dr A Prendiville Consultant Respiratory Paediatrician</td>
</tr>
</tbody>
</table>

All or part of this document can be released under the Freedom of Information Act 2000

This document is to be retained for 10 years from the date of expiry.

This document is only valid on the day of printing

Controlled Document
This document has been created following the Royal Cornwall Hospitals NHS Trust Policy on Document Production. It should not be altered in any way without the express permission of the author or their Line Manager.
### Appendix 2. Initial Equality Impact Assessment Screening Form

<table>
<thead>
<tr>
<th>Name of service, strategy, policy or project (hereafter referred to as policy) to be assessed: <strong>Infection Prevention &amp; Control Guidance on the Management of Patients with Tuberculosis</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Directorate and service area:</strong> Corporate, Infection Prevention</td>
<td><strong>Is this a new or existing Procedure?</strong> <strong>Existing</strong></td>
</tr>
<tr>
<td><strong>Name of individual completing assessment:</strong> Louise Dickinson</td>
<td><strong>Telephone:</strong> 01872 254969</td>
</tr>
</tbody>
</table>

1. **Policy Aim**
   - To protect patients, staff and the general public by preventing cross-infection and contamination of the environment.

2. **Policy Objectives**
   - To provide clear guidance on the necessary infection prevention & control measures to prevent the spread of Tuberculosis.

3. **Policy – intended Outcomes**
   - To reduce the risk of cross infections.

4. **How will you measure the outcome?**
   - Mandatory reporting.

5. **Who is intended to benefit from the Policy?**
   - All staff and patients.

6a. **Is consultation required with the workforce, equality groups, local interest groups etc. around this policy?**
   - **Yes**

   b. **If yes, have these groups been consulted?**
   - **Yes**

   c. **Please list any groups who have been consulted about this procedure.**
   - Infection Prevention and Control Steering Group
   - Hospital Infection Prevention and Control Committee
<table>
<thead>
<tr>
<th>Equality Group</th>
<th>Positive Impact</th>
<th>Negative Impact</th>
<th>No Impact</th>
<th>Reasons for decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Disability</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Religion or belief</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Transgender</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Pregnancy/ Maternity</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Sexual Orientation</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Marriage / Civil Partnership</td>
<td></td>
<td></td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>

You will need to continue to a full Equality Impact Assessment if the following have been highlighted:

- A negative impact and
- No consultation (this excludes any policies which have been identified as not requiring consultation).

8. If there is no evidence that the policy promotes equality, equal opportunities or improved relations - could it be adapted so that it does? How?

Full statement of commitment to policy of equal opportunities is included in the policy

Please sign and date this form.

**Keep one copy and send a copy to Matron, Equality, Diversity and Human Rights, c/o Royal Cornwall Hospitals NHS Trust, Human Resources Department, Chyvean House, Penventinnie Lane, Truro, Cornwall, TR1 3LJ**

A summary of the results will be published on the Trust's web site.

Signed: Louise Dickinson

Date: 1 July 2016